Literature DB >> 25411110

Mitochondrial (dys)function - a factor underlying the variability of efavirenz-induced hepatotoxicity?

M Polo1, F Alegre, H A Funes, A Blas-Garcia, V M Victor, J V Esplugues, N Apostolova.   

Abstract

BACKGROUND AND
PURPOSE: The non-nucleoside analogue reverse transcriptase inhibitor efavirenz is associated with hepatic toxicity and metabolic disturbances. Although the mechanisms involved are not clear, recent evidence has pinpointed a specific mitochondrial action of efavirenz accompanied by the induction of an endoplasmic reticulum (ER) stress/unfolded protein response in human hepatic cells. The aim of this study was to further investigate the involvement of this organelle by evaluating efavirenz's effects in cells lacking functional mitochondria (rho°) and comparing them with those of the typical mitotoxic agent rotenone, a standard complex I inhibitor, and the ER stress inducer thapsigargin. EXPERIMENTAL APPROACH: Hep3B rho(+) and rho° cells were treated with clinically relevant concentrations of efavirenz, then mitochondrial function and cytotoxicity were studied using standard cell biology techniques. KEY
RESULTS: Efavirenz-treated rho° cells exhibited a substantial reduction in parameters indicative of mitochondrial interference, such as increased superoxide production, mitochondrial mass/morphology alterations and enhanced expression of LONP, a highly conserved mitochondrial protease. In line with these results, the cytotoxic effect (cell number, chromatin condensation, cell cycle alterations and induction of apoptosis) of efavirenz was less pronounced in Hep3B respiration-depleted cells than in wild-type cells. The effect of efavirenz was both similar and different from those of two distinct mitochondrial stressors, thapsigargin and rotenone. CONCLUSIONS AND IMPLICATIONS: Cells lacking normal mitochondria (rho°) are less vulnerable to efavirenz. Our results provide further evidence that the hepatic damage induced by efavirenz involves acute interference with mitochondria and extend our knowledge of the response of mitochondria/ER to a stress stimulus.
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25411110      PMCID: PMC4376451          DOI: 10.1111/bph.13018

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  Thapsigargin directly induces the mitochondrial permeability transition.

Authors:  P Korge; J N Weiss
Journal:  Eur J Biochem       Date:  1999-10-01

2.  Metaphase arrest of Chinese hamster cells with rotenone.

Authors:  H M Meisner; L Sorensen
Journal:  Exp Cell Res       Date:  1966-05       Impact factor: 3.905

3.  Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy.

Authors:  Nadezda Apostolova; Leysa J Gomez-Sucerquia; Anna Gortat; Ana Blas-Garcia; Juan V Esplugues
Journal:  Hepatology       Date:  2011-08-02       Impact factor: 17.425

4.  Growing tissue-like constructs with Hep3B/HepG2 liver cells on PHBV microspheres of different sizes.

Authors:  Xin Hao Zhu; Chi-Hwa Wang; Yen Wah Tong
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2007-07       Impact factor: 3.368

5.  Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells.

Authors:  Ana Blas-García; Nadezda Apostolova; Daniel Ballesteros; Daniel Monleón; Jose M Morales; Milagros Rocha; Victor M Victor; Juan V Esplugues
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

6.  Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.

Authors:  M A Loko; F Bani-Sadr; M Winnock; K Lacombe; P Carrieri; D Neau; P Morlat; L Serfaty; F Dabis; D Salmon
Journal:  J Viral Hepat       Date:  2011-01-11       Impact factor: 3.728

7.  Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens.

Authors:  Karen T Tashima; Linda Bausserman; Elizabeth N Alt; Esther Aznar; Timothy P Flanigan
Journal:  HIV Clin Trials       Date:  2003 Jan-Feb

8.  Mitochondrial genome depletion in human liver cells abolishes bile acid-induced apoptosis: role of the Akt/mTOR survival pathway and Bcl-2 family proteins.

Authors:  Jose J G Marin; Alicia Hernandez; Isabel E Revuelta; Ester Gonzalez-Sanchez; Jose M Gonzalez-Buitrago; Maria J Perez
Journal:  Free Radic Biol Med       Date:  2013-04-16       Impact factor: 7.376

Review 9.  Efavirenz: a decade of clinical experience in the treatment of HIV.

Authors:  Franco Maggiolo
Journal:  J Antimicrob Chemother       Date:  2009-09-18       Impact factor: 5.790

10.  Mitochondrial DNA subhaplogroups L0a2 and L2a modify susceptibility to peripheral neuropathy in malawian adults on stavudine containing highly active antiretroviral therapy.

Authors:  Elizabeth Kampira; Johnstone Kumwenda; Joep J van Oosterhout; Collet Dandara
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

View more
  14 in total

1.  Role of p62/SQSTM1 beyond autophagy: a lesson learned from drug-induced toxicity in vitro.

Authors:  Fernando Alegre; Ángela B Moragrega; Miriam Polo; Alberto Marti-Rodrigo; Juan V Esplugues; Ana Blas-Garcia; Nadezda Apostolova
Journal:  Br J Pharmacol       Date:  2018-01-06       Impact factor: 8.739

2.  Lon protease: a novel mitochondrial matrix protein in the interconnection between drug-induced mitochondrial dysfunction and endoplasmic reticulum stress.

Authors:  Miriam Polo; Fernando Alegre; Angela B Moragrega; Lara Gibellini; Alberto Marti-Rodrigo; Ana Blas-Garcia; Juan V Esplugues; Nadezda Apostolova
Journal:  Br J Pharmacol       Date:  2017-11-07       Impact factor: 8.739

Review 3.  Safety implications of combined antiretroviral and anti-tuberculosis drugs.

Authors:  Maddalena Cerrone; Margherita Bracchi; Sean Wasserman; Anton Pozniak; Graeme Meintjes; Karen Cohen; Robert J Wilkinson
Journal:  Expert Opin Drug Saf       Date:  2019-12-06       Impact factor: 4.250

Review 4.  Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.

Authors:  Antonio Segovia-Zafra; Daniel E Di Zeo-Sánchez; Carlos López-Gómez; Zeus Pérez-Valdés; Eduardo García-Fuentes; Raúl J Andrade; M Isabel Lucena; Marina Villanueva-Paz
Journal:  Acta Pharm Sin B       Date:  2021-11-18       Impact factor: 11.413

5.  3D Spheroids of Human Primary Urine-Derived Stem Cells in the Assessment of Drug-Induced Mitochondrial Toxicity.

Authors:  Huifen Ding; Kalyani Jambunathan; Guochun Jiang; David M Margolis; Iris Leng; Michael Ihnat; Jian-Xing Ma; Jon Mirsalis; Yuanyuan Zhang
Journal:  Pharmaceutics       Date:  2022-05-11       Impact factor: 6.525

Review 6.  Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System.

Authors:  Luc Bertrand; Madhavan Nair; Michal Toborek
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 7.  Mitochondrial Lon protease at the crossroads of oxidative stress, ageing and cancer.

Authors:  Marcello Pinti; Lara Gibellini; Yongzhang Liu; Shan Xu; Bin Lu; Andrea Cossarizza
Journal:  Cell Mol Life Sci       Date:  2015-09-12       Impact factor: 9.261

8.  Combination of Tenofovir and Emtricitabine with Efavirenz Does Not Moderate Inhibitory Effect of Efavirenz on Mitochondrial Function and Cholesterol Biosynthesis in Human T Lymphoblastoid Cell Line.

Authors:  Min Li; Anuoluwapo Sopeyin; Elijah Paintsil
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

9.  Acute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir.

Authors:  Rashmee Patil; Mel A Ona; Haris Papafragkakis; Jeanne Carey; Yitzchak Moshenyat; Adib Alhaddad; Sury Anand
Journal:  Case Reports Hepatol       Date:  2015-06-16

10.  Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy.

Authors:  Sumanth Karamchand; Rory Leisegang; Michael Schomaker; Gary Maartens; Lourens Walters; Michael Hislop; Joel A Dave; Naomi S Levitt; Karen Cohen
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.